CI Cigna
$300.49
▲ 0.6%Updated Oct 16, 2:25 PM ET
Report Card
CI at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Favorable · 60/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▼ Down 11.2% in the year to Jul 6, 2026
Key Metrics
Market Cap
$76.12B
P/E
12.63x
Forward P/E (est.)
9.68x
ROE
15.2%
Revenue Growth
8.8%
EPS Growth
30.5%
Profit Margin
2.3%
FCF Yield
9.7%
Debt / Equity
0.75x
ROIC
9.0%
Interest Coverage
—
Current Ratio
0.85x
Dividend Yield
2.1%
Implied Growth (rev. DCF)
—
Rating Score
60/100
Business Overview
Cigna (CI) is a large-cap company in the Health Care Services industry, part of the Health Care sector of the S&P 500, with a market value around $76.12B.
In its latest reported year it generated about $274.90B in revenue and $5.96B in net profit.
Our model rates CI Favorable (60/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedSome durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
3.8% average over the last 3 years
±2.0 pts around 5.7% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 10 of 10 years
9.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CI's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CI trades near $300.49, above its 50-day average ($284.76) and 200-day average ($280.45). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 43 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. CI's is $6.68 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, CI found buyers near $273.66 (support) and sellers near $299.27 (resistance); its 52-week range then was $239.51–$332.29. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.2× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
12.1%
Revenue moved from $39.84B in 2016 to $274.90B in 2025, a 23.9% compound annual growth rate. The most recent year grew a steady 8.8% year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
9.2%
Operating Margin
3.3%
Net Margin
2.2%
ROE
15.2%
Cigna keeps about 2.3% of each sales dollar as net profit, with a 9.2% gross margin and 3.3% operating margin. Return on equity is 15.2% and return on invested capital about 9.0%. Thin margins leave less cushion if costs rise.
Debt Analysis
Total Debt
$39.52B
Net Debt
$33.23B
Net Debt / EBITDA
3.61x
Debt / Equity
0.75x
Leverage: debt-to-equity is 0.8x, with a current ratio of 0.8x. That is a moderate, manageable debt load for most businesses. It carries roughly $39.52B of total debt against $6.30B of cash.
Cash Flow Analysis
Operating CF
$9.60B
Free Cash Flow
$9.60B
FCF Margin
3.5%
In the latest year Cigna produced about $9.60B of operating cash flow and $9.60B of free cash flow after capital spending. That is a free-cash-flow yield of about 9.7% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
Dividend Safety
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
What to look for in a dividend stockThe payout is comfortably covered by cash the business actually generates, with a raise habit behind it.
Dividend yield
2.1%
Per share (latest FY)
$6.04
Total paid (latest FY)
$1.61B
History on record
10 years
dividend uses 17% of free cash flow
27% of net income paid out
total dividends increased 5 years in a row
no cuts in the last 10 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
Valuation Analysis
P/E
12.63x
P/S
0.28x
P/B
1.81x
EV / EBITDA
—
CI trades at 12.6x trailing earnings (about 9.7x on estimated forward earnings), 0.3x sales, and 1.8x book value. That is an undemanding multiple — potentially cheap if the business is stable.
Metrics vs. Sector Range
Where CI sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How CI stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, CI ranks #28 by our overall rating. It trades at a discount versus the sector on earnings (12.6x P/E vs. 26.1x median) with a higher return on equity (15.2% vs. 14.1%) and faster revenue growth (8.8% vs. 7.6%).
P/E vs sector
12.6x
median 26.1x
ROE vs sector
15.2%
median 14.1%
Growth vs sector
8.8%
median 7.6%
Sector rank
#28
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$400.70 – $651.14
vs. $300.49 today · implied CAGR 6% – 17%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $299.64B | $326.61B | $356.00B | $388.04B | $422.97B |
| Net income | $8.99B | $9.80B | $10.68B | $11.64B | $12.69B |
| EPS | $35.48 | $38.68 | $42.16 | $45.95 | $50.09 |
| Share price (low) | $283.87 | $309.42 | $337.26 | $367.62 | $400.70 |
| Share price (high) | $461.29 | $502.80 | $548.06 | $597.38 | $651.14 |
| CAGR (low–high) | -6% / 54% | 1% / 29% | 4% / 22% | 5% / 19% | 6% / 17% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for CI:
- Strong return on equity (15.2%) shows capital is put to work well.
- Healthy free-cash-flow yield (~9.7%) funds buybacks and dividends.
- Pays a 2.1% dividend on top of any price gains.
- Our model's overall read is Favorable (60/100).
Bear Case
The case against CI:
- Thin net margins (2.3%) leave little room for error.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Margin risk — thin profitability (2.3%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen favourably: Cigna is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 12.6x earnings, which our model scores Favorable (60/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
CI's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
In the Idea Lab
CI — frequently asked questions
Is CI a good stock to buy?
We don't give buy or sell advice. Our model rates Cigna Favorable (60/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is CI's rating on The Stocks School?
Cigna currently scores 60/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does CI's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Cigna's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for CI calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this CI analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell CI. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.